Catharina G Faber

List of Publications by Year
in descending order

162 papers	9,381 citations	34105 52 h-index	48315 88 g-index
166 all docs	166 docs citations	166 times ranked	6866 citing authors

#	Article	IF	Citations
1	Gain of function Na_V1.7 mutations in idiopathic small fiber neuropathy. Annals of Neurology, 2012, 71, 26-39.	5.3	518
2	Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. Journal of the Peripheral Nervous System, 2010, 15, 202-207.	3.1	462
3	Gain-of-function Na _v 1.8 mutations in painful neuropathy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19444-19449.	7.1	369
4	Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology, 2011, 76, 337-345.	1.1	267
5	Gain-of-function mutations in sodium channel NaV1.9 in painful neuropathy. Brain, 2014, 137, 1627-1642.	7.6	242
6	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Annals of Oncology, 2013, 24, 454-462.	1.2	232
7	Modifying the Medical Research Council grading system through Rasch analyses. Brain, 2012, 135, 1639-1649.	7.6	224
8	Hereditary muscular dystrophies and the heart. Neuromuscular Disorders, 2010, 20, 479-492.	0.6	215
9	Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology, 2009, 73, 1142-1148.	1.1	206
10	Small fibre neuropathy in sarcoidosis. Lancet, The, 2002, 359, 2085-2086.	13.7	199
11	Spinal Cord Stimulation and Pain Relief in Painful Diabetic Peripheral Neuropathy: A Prospective Two-Center Randomized Controlled Trial. Diabetes Care, 2014, 37, 3016-3024.	8.6	193
12	Small-fibre neuropathiesâ€"advances in diagnosis, pathophysiology and management. Nature Reviews Neurology, 2012, 8, 369-379.	10.1	187
13	Small fiber neuropathy: a common and important clinical disorder. Journal of the Neurological Sciences, 2004, 227, 119-130.	0.6	183
14	Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurology, The, 2010, 9, 245-253.	10.2	170
15	Sodium channel genes in pain-related disorders: phenotypeâ€"genotype associations and recommendations for clinical use. Lancet Neurology, The, 2014, 13, 1152-1160.	10.2	148
16	Variant CCG and GGC repeats within the CTG expansion dramatically modify mutational dynamics and likely contribute toward unusual symptoms in some myotonic dystrophy type 1 patients. Human Molecular Genetics, 2010, 19, 1399-1412.	2.9	139
17	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Annals of Oncology, 2014, 25, 257-264.	1.2	136
18	16.â€,Complex Regional Pain Syndrome. Pain Practice, 2011, 11, 70-87.	1.9	127

#	Article	IF	Citations
19	Revised normative values for grip strength with the Jamar dynamometer. Journal of the Peripheral Nervous System, 2011, 16, 47-50.	3.1	118
20	Incidence and prevalence of small-fiber neuropathy. Neurology, 2013, 81, 1356-1360.	1.1	114
21	Small-Fiber Neuropathy Nav1.8 Mutation Shifts Activation to Hyperpolarized Potentials and Increases Excitability of Dorsal Root Ganglion Neurons. Journal of Neuroscience, 2013, 33, 14087-14097.	3.6	107
22	Small fibers, large impact: Quality of life in smallâ€fiber neuropathy. Muscle and Nerve, 2014, 49, 329-336.	2.2	102
23	Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Lancet Neurology, The, 2018, 17, 671-680.	10.2	95
24	Intra- and Interfamily Phenotypic Diversity in Pain Syndromes Associated with a Gain-of-Function Variant of Na_V1.7. Molecular Pain, 2011, 7, 1744-8069-7-92.	2.1	94
25	Small fibre neuropathy. Current Opinion in Neurology, 2012, 25, 542-549.	3.6	94
26	Associated conditions in small fiber neuropathy â€“ a large cohort study and review of the literature. European Journal of Neurology, 2018, 25, 348-355.	3.3	94
27	Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small fibre neuropathy. Brain, 2012, 135, 2613-2628.	7.6	90
28	Changing outcome in inflammatory neuropathies. Neurology, 2014, 83, 2124-2132.	1.1	89
29	Na _v 1.7-related small fiber neuropathy. Neurology, 2012, 78, 1635-1643.	1.1	86
30	Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet Journal of Rare Diseases, 2012, 7, 73.	2.7	86
31	Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain, 2019, 142, 263-275.	7.6	85
32	196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8â€“10 February 2013, Naarden, The Netherlands. Neuromuscular Disorders, 2013, 23, 924-933.	0.6	82
33	Painful neuropathies: the emerging role of sodium channelopathies. Journal of the Peripheral Nervous System, 2014, 19, 53-65.	3.1	82
34	The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 499-505.	1.9	80
35	Small fiber neuropathy in Fabry disease. Molecular Genetics and Metabolism, 2012, 106, 135-141.	1.1	79
36	Paroxysmal itch caused by gain-of-function Nav1.7 mutation. Pain, 2014, 155, 1702-1707.	4.2	78

#	Article	IF	Citations
37	Entrapment in anti myelin-associated glycoprotein neuropathy. Journal of Neurology, 2009, 256, 620-624.	3.6	75
38	Greater corneal nerve loss at the inferior whorl is related to the presence of diabetic neuropathy and painful diabetic neuropathy. Scientific Reports, 2018, 8, 3283.	3.3	74
39	Abnormal warm and cold sensation thresholds suggestive of small-fibre neuropathy in sarcoidosis. Clinical Neurophysiology, 2003, 114, 2326-2333.	1.5	73
40	Severity of Neuropathy Is Associated With Long-term Spinal Cord Stimulation Outcome in Painful Diabetic Peripheral Neuropathy: Five-Year Follow-up of a Prospective Two-Center Clinical Trial. Diabetes Care, 2018, 41, 32-38.	8.6	73
41	AChR deficiency due to Îµ-subunit mutations: two common mutations in the Netherlands. Journal of Neurology, 2009, 256, 1719-1723.	3.6	72
42	Smallâ€fiber neuropathy: Expanding the clinical pain universe. Journal of the Peripheral Nervous System, 2019, 24, 19-33.	3.1	71
43	The Domain II S4-S5 Linker in Nav1.9: A Missense Mutation Enhances Activation, Impairs Fast Inactivation, and Produces Human Painful Neuropathy. NeuroMolecular Medicine, 2015, 17, 158-169.	3.4	70
44	Small nerve fibres, small hands and small feet: a new syndrome of pain, dysautonomia and acromesomelia in a kindred with a novel NaV1.7 mutation. Brain, 2012, 135, 345-358.	7.6	69
45	Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta OncolÃ³gica, 2015, 54, 463-469.	1.8	67
46	Sustained Treatment Effect of Spinal Cord Stimulation in Painful Diabetic Peripheral Neuropathy: 24-Month Follow-up of a Prospective Two-Center Randomized Controlled Trial. Diabetes Care, 2015, 38, e132-e134.	8.6	67
47	Painful peripheral neuropathy and sodium channel mutations. Neuroscience Letters, 2015, 596, 51-59.	2.1	66
48	Structural and functional cardiac changes in myotonic dystrophy type 1: a cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 48.	3.3	64
49	Revising two-point discrimination assessment in normal aging and in patients with polyneuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 832-834.	1.9	63
50	Pain relief and quality-of-life improvement after spinal cord stimulation in painful diabetic polyneuropathy: a pilot study. British Journal of Anaesthesia, 2012, 109, 623-629.	3.4	62
51	Predictors of Pain Relieving Response to Sympathetic Blockade in Complex Regional Pain Syndrome Type 1. Anesthesiology, 2012, 116, 113-121.	2.5	61
52	Diagnosis of Neuropathy and Risk Factors for Corneal Nerve Loss in Type 1 and Type 2 Diabetes: A Corneal Confocal Microscopy Study. Diabetes Care, 2021, 44, 150-156.	8.6	60
53	Brushâ€evoked allodynia predicts outcome of spinal cord stimulation in Complex Regional Pain Syndrome type 1. European Journal of Pain, 2010, 14, 164-169.	2.8	58
54	Contact heat evoked potentials: Normal values and use in smallâ€fiber neuropathy. Muscle and Nerve, 2015, 51, 743-749.	2.2	58

#	Article	IF	Citations
55	Improving fatigue assessment in immuneâ€mediated neuropathies: the modified Raschâ€built fatigue severity scale. Journal of the Peripheral Nervous System, 2009, 14, 268-278.	3.1	54
56	Fatigue and daytime sleepiness scale in myotonic dystrophy type 1. Muscle and Nerve, 2013, 47, 89-95.	2.2	52
57	Neuropathyâ€associated Na_V1.7 variant I228M impairs integrity of dorsal root ganglion neuron axons. Annals of Neurology, 2013, 73, 140-145.	5.3	52
58	The minimum clinically important difference: which direction to take. European Journal of Neurology, 2019, 26, 850-855.	3.3	52
59	Review: Electrical spinal cord stimulation in painful diabetic polyneuropathy, a systematic review on treatment efficacy and safety. European Journal of Pain, 2011, 15, 783-788.	2.8	49
60	Idiopathic distal sensory polyneuropathy. Neurology, 2020, 95, 1005-1014.	1.1	49
61	Morphometry of dermal nerve fibers in human skin. Neurology, 2011, 77, 242-249.	1.1	48
62	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurology, The, 2018, 17, 689-698.	10.2	48
63	Yield of peripheral sodium channels gene screening in pure small fibre neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 342-352.	1.9	47
64	Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy. Neurology, 2021, 96, e2534-e2545.	1.1	43
65	Ca²⁺ toxicity due to reverse Na⁺/Ca²⁺ exchange contributes to degeneration of neurites of DRG neurons induced by a neuropathy-associated Nav1.7 mutation. Journal of Neurophysiology, 2015, 114, 1554-1564.	1.8	41
66	Corneal confocal microscopy detects small nerve fibre damage in patients with painful diabetic neuropathy. Scientific Reports, 2020, 10, 3371.	3.3	41
67	Outcome measures in immuneâ€mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. Journal of the Peripheral Nervous System, 2008, 13, 136-147.	3.1	40
68	Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ). Neuromuscular Disorders, 2010, 20, 310-318.	0.6	40
69	Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. Neuromuscular Disorders, 2018, 28, 402-407.	0.6	40
70	The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 Td (Po	0.6	39
71	Genetic aspects of sodium channelopathy in small fiber neuropathy. Clinical Genetics, 2012, 82, 351-358.	2.0	38
72	Raschâ€built Overall Disability Scale for Multifocal motor neuropathy (<scp>MMNâ€RODS</scp>^{Â©}). Journal of the Peripheral Nervous System, 2015, 20, 296-305.	3.1	38

#	Article	IF	Citations
73	A gain-of-function sodium channelÎ²2-subunit mutation in painful diabetic neuropathy. Molecular Pain, 2019, 15, 174480691984980.	2.1	38
74	Temperature threshold testing: a systematic review. Journal of the Peripheral Nervous System, 2013, 18, 7-18.	3.1	37
75	Swallowing assessment in myotonic dystrophy type 1 using fiberoptic endoscopic evaluation of swallowing (FEES). Neuromuscular Disorders, 2014, 24, 1054-1062.	0.6	37
76	Raschâ€ionale for neurologists. Journal of the Peripheral Nervous System, 2015, 20, 260-268.	3.1	37
77	Correspondence between neurophysiological andÂclinical measurements of chemotherapyâ€induced peripheral neuropathy: secondary analysis of data fromÂthe <scp>CIâ€PeriNomS</scp> study. Journal of the Peripheral Nervous System, 2014, 19, 127-135.	3.1	36
78	Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). European Journal of Cancer, 2013, 49, 2910-2918.	2.8	35
79	Improving assessment in small fiber neuropathy. Journal of the Peripheral Nervous System, 2015, 20, 333-340.	3.1	34
80	Second intravenous immunoglobulin dose in patients with Guillain-BarrÃ© syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 275-283.	10.2	34
81	The Role of Sodium Channels in Painful Diabetic and Idiopathic Neuropathy. Current Diabetes Reports, 2014, 14, 538.	4.2	33
82	Correlation of the patient's reported outcome Inflammatoryâ€<scp>RODS</scp> with an objective metric in immuneâ€mediated neuropathies. European Journal of Neurology, 2016, 23, 1248-1253.	3.3	33
83	Channelopathies, painful neuropathy, and diabetes: which way does the causal arrow point?. Trends in Molecular Medicine, 2014, 20, 544-550.	6.7	32
84	Reconstructing the Rasch-Built Myotonic Dystrophy Type 1 Activity and Participation Scale. PLoS ONE, 2015, 10, e0139944.	2.5	32
85	Peripheral neuropathy in myotonic dystrophy type 1. Journal of the Peripheral Nervous System, 2011, 16, 24-29.	3.1	31
86	Differential effect of lacosamide on Nav1.7 variants from responsive and non-responsive patients with small fibre neuropathy. Brain, 2020, 143, 771-782.	7.6	31
87	Impairment measures versus inflammatory <scp>RODS</scp> in <scp>GBS</scp> and <scp>CIDP</scp>: a responsiveness comparison. Journal of the Peripheral Nervous System, 2015, 20, 289-295.	3.1	30
88	No Fabry Disease in Patients Presenting with Isolated Small Fiber Neuropathy. PLoS ONE, 2016, 11, e0148316.	2.5	30
89	Network topology of NaV1.7 mutations in sodium channel-related painful disorders. BMC Systems Biology, 2017, 11, 28.	3.0	29
90	Pain and autonomic dysfunction in patients with sarcoidosis and small fibre neuropathy. Journal of Neurology, 2010, 257, 2086-2090.	3.6	28

#	Article	IF	Citations
91	Sodium Channel Nav1.7 in Vascular Myocytes, Endothelium, and Innervating Axons in Human Skin. Molecular Pain, 2015, 11, s12990-015-0024.	2.1	28
92	Grip strength comparison in immuneâ€mediated neuropathies: Vigorimeter vs. Jamar. Journal of the Peripheral Nervous System, 2015, 20, 269-276.	3.1	28
93	Comparing the <scp>NIS</scp> vs. <scp>MRC</scp> and <scp>INCAT</scp> sensory scale through Rasch analyses. Journal of the Peripheral Nervous System, 2015, 20, 277-288.	3.1	27
94	Diabetic Neuropathy Is Characterized by Progressive Corneal Nerve Fiber Loss in the Central and Inferior Whorl Regions. , 2020, 61, 48.		26
95	Advances in diagnostics and outcome measures in peripheral neuropathies. Neuroscience Letters, 2015, 596, 3-13.	2.1	25
96	COL6A5variants in familial neuropathic chronic itch. Brain, 2017, 140, aww343.	7.6	25
97	Nav1.7: Stress-Induced Changes in Immunoreactivity within Magnocellular Neurosecretory Neurons of the Supraoptic Nucleus. Molecular Pain, 2013, 9, 1744-8069-9-39.	2.1	24
98	Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects. Drugs and Aging, 2015, 32, 611-621.	2.7	24
99	Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial. Trials, 2016, 17, 330.	1.6	24
100	Fatigue in immune-mediated neuropathies. Neuromuscular Disorders, 2012, 22, S203-S207.	0.6	23
101	Spinal Cord Stimulation in Complex Regional Pain Syndrome Type I of Less Than 12-Month Duration. Neuromodulation, 2012, 15, 144-150.	0.8	23
102	Sustained effect of spinal cord stimulation on pain and quality of life in painful diabetic peripheral neuropathy. British Journal of Anaesthesia, 2013, 111, 1030-1031.	3.4	23
103	A painful neuropathy-associated Nav1.7 mutant leads to time-dependent degeneration of small-diameter axons associated with intracellular Ca²⁺dysregulation and decrease in ATP levels. Molecular Pain, 2016, 12, 174480691667447.	2.1	23
104	Predicting Outcome in Guillain-BarrÃ© Syndrome. Neurology, 2022, 98, .	1.1	22
105	A Trial-Based Economic Evaluation Comparing Spinal Cord Stimulation With Best Medical Treatment in Painful Diabetic Peripheral Neuropathy. Journal of Pain, 2017, 18, 405-414.	1.4	20
106	Patients' and physicians' interpretation of chemotherapyâ€induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, 111-119.	3.1	20
107	Outcome measures in peripheral neuropathies. Current Opinion in Neurology, 2012, 25, 556-563.	3.6	18
108	Electrocardiographic predictors of infrahissian conduction disturbances in myotonic dystrophy type 1. Europace, 2021, 23, 298-304.	1.7	18

#	Article	IF	Citations
109	The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands. Neuromuscular Disorders, 2016, 26, 447-452.	0.6	17
110	Quality of life in inflammatory neuropathies: the IN-QoL. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 256-262.	1.9	17
111	Instruments for the Assessment of Behavioral and Psychosocial Functioning in Duchenne and Becker Muscular Dystrophy; a Systematic Review of the Literature. Journal of Pediatric Psychology, 2019, 44, 1205-1223.	2.1	17
112	Evaluation of molecular inversion probe versus TruSeqÂ® custom methods for targeted next-generation sequencing. PLoS ONE, 2020, 15, e0238467.	2.5	17
113	Expression of pathogenic SCN9A mutations in the zebrafish: A model to study small-fiber neuropathy. Experimental Neurology, 2019, 311, 257-264.	4.1	16
114	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. Neurology, 2021, 97, e660-e672.	1.1	16
115	Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain, 2022, 145, 1641-1652.	7.6	16
116	Optimizing temperature threshold testing in small-fiber neuropathy. Muscle and Nerve, 2015, 51, 870-876.	2.2	15
117	Corneal confocal microscopy compared with quantitative sensory testing and nerve conduction for diagnosing and stratifying the severity of diabetic peripheral neuropathy. BMJ Open Diabetes Research and Care, 2020, 8, e001801.	2.8	15
118	Differential effect of D623N variant and wild-type Nav1.7 sodium channels on resting potential and interspike membrane potential of dorsal root ganglion neurons. Brain Research, 2013, 1529, 165-177.	2.2	14
119	The <scp>Val30Met</scp> familial amyloid polyneuropathy specific Raschâ€built overall disability scale (<scp>FAPâ€RODS</scp>^{Â©}). Journal of the Peripheral Nervous System, 2015, 20, 319-327.	3.1	14
120	Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trialâ€“the LENSS study. Trials, 2016, 17, 306.	1.6	14
121	Small Fiber Neuropathy in Children: Two Case Reports Illustrating the Importance of Recognition. Pediatrics, 2016, 138, .	2.1	14
122	Dystrophin is expressed in smooth muscle and afferent nerve fibers in the rat urinary bladder. Muscle and Nerve, 2019, 60, 202-210.	2.2	14
123	Does ability to walk reflect general functionality in inflammatory neuropathies?. Journal of the Peripheral Nervous System, 2016, 21, 74-81.	3.1	13
124	Parental repeat length instability in myotonic dystrophy type 1 pre- and protomutations. European Journal of Human Genetics, 2020, 28, 956-962.	2.8	13
125	Corneal nerve loss is related to the severity of painful diabetic neuropathy. European Journal of Neurology, 2022, 29, 286-294.	3.3	13
126	Rasch analysis to evaluate the motor function measure for patients with facioscapulohumeral muscular dystrophy. International Journal of Rehabilitation Research, 2021, 44, 38-44.	1.3	13

#	Article	IF	Citations
127	Skin biopsy and small fibre neuropathies: facts and thoughts 30 years later. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 915-918.	1.9	12
128	Late onset axonal Charcot-Marie-Tooth phenotype caused by a novel myelin protein zero mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 534-537.	1.9	10
129	A zebrafish model to study small-fiber neuropathy reveals a potential role for GDAP1. Mitochondrion, 2019, 47, 273-281.	3.4	10
130	Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention-deficit hyperactivity disorder. European Journal of Paediatric Neurology, 2019, 23, 152-157.	1.6	10
131	Swallow-related quality of life and oropharyngeal dysphagia in myotonic dystrophy. European Archives of Oto-Rhino-Laryngology, 2020, 277, 2357-2362.	1.6	10
132	Diagnosis of neuropathic pain: challenges and possibilities. Expert Opinion on Medical Diagnostics, 2012, 6, 89-93.	1.6	9
133	An overview of predictors for persistent neuropathic pain. Expert Review of Neurotherapeutics, 2013, 13, 505-513.	2.8	9
134	Outcome measures in <scp>MMN</scp> revisited: further improvement needed. Journal of the Peripheral Nervous System, 2015, 20, 306-318.	3.1	9
135	Myotonic discharges discriminate chloride from sodium muscle channelopathies. Neuromuscular Disorders, 2015, 25, 73-80.	0.6	9
136	The small fiber neuropathy NaV1.7 I228M mutation: impaired neurite integrity via bioenergetic and mitotoxic mechanisms, and protection by dexpramipexole. Journal of Neurophysiology, 2020, 123, 645-657.	1.8	9
137	Two independent mouse lines carrying the Nav1.7 I228M gain-of-function variant display dorsal root ganglion neuron hyperexcitability but a minimal pain phenotype. Pain, 2021, 162, 1758-1770.	4.2	9
138	Peripheral Ion Channel Gene Screening in Painful- and Painless-Diabetic Neuropathy. International Journal of Molecular Sciences, 2022, 23, 7190.	4.1	9
139	Outcome measures in Duchenne muscular dystrophy: Are we ready for the new therapeutic era?. Neuromuscular Disorders, 2009, 19, 447.	0.6	8
140	The facioscapulohumeral muscular dystrophy Raschâ€built overall disability scale (FSHDâ€RODS). European Journal of Neurology, 2021, 28, 2339-2348.	3.3	8
141	Encephalopathic attacks in a family co-segregating myotonic dystrophy type 1, an intermediate Charcot-Marie-Tooth neuropathy and early hearing loss. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1029-1035.	1.9	7
142	Painful Diabetic Neuropathy Anxiety Raschâ€Transformed Questionnaire (<scp>PARTâ€Q30</scp>^{Â©}). Journal of the Peripheral Nervous System, 2016, 21, 96-104.	3.1	7
143	Activities of daily living in myotonic dystrophy type 1. Acta Neurologica Scandinavica, 2020, 141, 380-387.	2.1	7
144	Validation of the Serbian version of inflammatory Raschâ€built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System, 2019, 24, 260-267.	3.1	6

#	Article	IF	Citations
145	Hydropathicity-based prediction of pain-causing NaV1.7 variants. BMC Bioinformatics, 2021, 22, 212.	2.6	5
146	Prevalence of Bladder and Bowel Dysfunction in Duchenne Muscular Dystrophy Using the Childhood Bladder and Bowel Dysfunction Questionnaire. Life, 2021, 11, 772.	2.4	5
147	A novel gain-of-function sodium channel Î²2 subunit mutation in idiopathic small fiber neuropathy. Journal of Neurophysiology, 2021, 126, 827-839.	1.8	5
148	Lacosamide Inhibition of NaV1.7 Channels Depends on its Interaction With the Voltage Sensor Domain and the Channel Pore. Frontiers in Pharmacology, 2021, 12, 791740.	3.5	5
149	MRC sumâ€score in the ICU: Good reliability does not necessarily reflect â€œtrue reliabilityâ€• Muscle and Nerve, 2012, 45, 767-768.	2.2	4
150	Computational pipeline to probe NaV1.7 gain-of-function variants in neuropathic painful syndromes. Scientific Reports, 2020, 10, 17930.	3.3	3
151	Change over time in ability to perform activities of daily living in myotonic dystrophy type 1. Journal of Neurology, 2020, 267, 3235-3242.	3.6	3
152	Non-extensitivity and criticality of atomic hydropathicity around a voltage-gated sodium channelâ€™s pore: a modeling study. Journal of Biological Physics, 2021, 47, 61-77.	1.5	3
153	Cumulative hydropathic topology of a voltageâ€gated sodium channel at atomic resolution. Proteins: Structure, Function and Bioinformatics, 2020, 88, 1319-1328.	2.6	3
154	Approach to Small Fiber Neuropathy. , 2014, , 507-517.		2
155	Morphometry of dermal nerve fibers in human skin. Neurology, 2011, 77, 1770-1770.	1.1	1
156	Peripheral neuropathies: Moving closer to mechanism. Neuroscience Letters, 2015, 596, 1-2.	2.1	1
157	The Pain Dynamics of Small Fiber Neuropathy. Journal of Pain, 2019, 20, 655-663.	1.4	1
158	The risks of using non-specific outcome measures to capture activities of daily living in myotonic dystrophy type 2. Neuromuscular Disorders, 2021, 31, 367-368.	0.6	1
159	The applicability of the digit wrinkle scan to quantify sympathetic nerve function. Clinical Neurophysiology Practice, 2022, 7, 115-119.	1.4	1
160	Author Response: Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy. Neurology, 2021, 97, 794.2-795.	1.1	1
161	An evaluation of 24â€…h Holter monitoring in patients with myotonic dystrophy type 1. Europace, 0, , .	1.7	1
162	Follow-up Author Response: Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy. Neurology, 2022, 98, 129-130.	1.1	0